Arbutus Biopharma Corporation ABUS Return on assets
Return on assets at other companies
Other financials
Where this comes from
Calculated from Arbutus Biopharma Corporation’s reported figures.
Based on trailing twelve months.
The official record: Arbutus Biopharma Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arbutus Biopharma Corporation's return on assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arbutus Biopharma Corporation's return on assets?
- Arbutus Biopharma Corporation (ABUS) reported return on assets of 81.5% in Q1 2026.
- How has Arbutus Biopharma Corporation's return on assets changed year-over-year?
- Arbutus Biopharma Corporation's return on assets increased by 242.3% year-over-year, from -57.3% to 81.5%.
- What is the long-term trend for Arbutus Biopharma Corporation's return on assets?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's return on assets has grown at a -10.8% compound annual growth rate (CAGR), from -52.5% to -29.6%.
- What does return on assets mean?
- Trailing-twelve-month net income divided by average total assets. Measures how efficiently the asset base generates profit, independent of how those assets are financed. Computed as net income over average total assets — note this is OpenCapital's standard definition and may differ from data vendors that use alternative numerators.